乙型肝炎及其相关病变中FoxB1检测和临床意义

FoxBl expression and its clinical significance in hepatitis B and its relative diseases

目的研究FoxB1在乙型肝炎发生、发展中表达的临床意义。方法①收集临床确诊为乙型肝炎并排除甲、丙、丁、戊型肝炎病毒合并感染的乙肝住院病人血清278例，其中进展为肝硬化阶段者14例，肝癌阶段者12例，并随机抽取60名健康者血清，检测乙型肝炎病毒（HBV）DNA载量、FoxB1浓度和丙氨酸氨基转移酶活性；②分析乙型肝炎病人血清中FoxB1浓度与HBV—DNA载量谷丙转氨酶（ALT）活性的相关性，并依据乙型肝炎患者不同病情进展程度，分别比较肝癌组、肝硬化组、乙型肝炎组与健康组之间FoxB1因子浓度的差异。结果@278例肝炎病人血清中，HBV—DNA载量≥10^5拷贝／ml组FoxB1因子浓度为（12．5±6．9）pg／ml，HBV—DNA载量〈10^5拷贝／ml组为（12．7±9．3）pg／ml，健康人群组为（12．2±9．7）pg／ml，三组间FoxB1浓度无统计学意义（P〉0．05）。②278例ALT异常组血清中FoxB1浓度为（17．4±20．5）pg／ml，健康对照组血清中FoxB1浓度为（12．2±9．7）pg／ml，ALT异常组FoxB1浓度略高于健康对照组（P〈0．05），血清FoxB1水平与ALT呈正相关（r=0．701）。③乙型肝炎组FoxB1浓度为（12．6±8．7）pg／ml，肝硬化组为（60．1±38．1）pg／ml、肝癌组为（68．5±37．3）pg／ml，肝癌组、肝硬化组中FoxB1浓度显著高于乙型肝炎组（P〈0．05），而肝癌组与肝硬化组之间比较差异无统计学意义（P〉0．05）。结论FoxB1水平与肝细胞损伤ALT释放有关，可能参与肝癌病变，对乙型肝炎演化为肝硬化、肝癌有一定的预示作用，可作为病情进展的风险因子，并且可能成为治疗乙型肝炎病毒所致肝硬化、肝癌的新靶标。’

Objective To investigate the clinical significance of FoxB1 in the hepatitis B＇ s occurrence and development. Method ①Except infected with hepatitis A, C, D or E virus ,Sera of 278 hepatitis B pa-tients were collected,in which 14 were cirrus patients and 12 were hepatocellular carcinoma （HCC） patients. 60 sera of healthy were also collected. Concentration of FoxB1 factor was detected in these sera. And other rele-vant clinical information, alanine transaminase （ALT） activity data and hepatitis B virus （HBV） DNA copies were collected. ②The correlation was analyzed among the concentration of FoxB1 factors, HBV-DNA and ALT activity. Furthermore ,the differences was analyzed on concentration of FoxB1 factors in the groups of liver canc-er, liver cirrhosis, Hepatitis B and the healthy. Results ①In 278 cases of hepatitis B patients, FoxB1 of 〉/ 105 copies/ml group was （ 12.5 ± 6.9 ） pg/ml, and 〈 105 group was （ 12. 7 ± 9. 3 ） pg/ml, and healthy control was （12. 2 ±9.7）pg/ml. There is no significant FoxB1 factors differenceamong the three groups of ＂≥ 105 copies/ml group＂, ＂ 〈 105 copies/ml group ＂and＂ the healthy group＂ （ P 〈 0.05 ）. ②FoxB1 concentration was （ 17.4 ± 20. 5 ） pg/ml in 278 cases of sera with high ALT activity, healthy control was（ 12.2 ± 9.7 ） pg/ml. FoxB1 was higher in the high ALT group than in the healthy （ P 〈 0.05 ）. There was positively correlation be-tween concentration of FoxB1 factors and ALT activity （ r = 0. 701 ）. ③FoxB1 concentrations of the hepatitis B patients was（12. 6 ± 8.7）pg/ml, cirrhosis group was （60. 1 ± 38. 1 ）pg/ml, and liver cancer group was （68. 5 ± 37. 3）pg/ml. FoxB1 concentration was higher in cirrhosis and liver cancer groups than in hepatitis B group and healthy people （P 〈 0.05 ） ; There was no significant difference between in hepatocellular carcinoma group and cirrhosis group （P 〉 0. 05）. Conclusion FoxB1 is associated with hepatocyte damage and may in-volve in hepatocellular carcinogenesis. It may be foretell of liver cirrhosi and HCC occurrence as a risk factor for hepatitis B progression. In the future,FoxB1 may serve as a novel target for liver cirrhosis and HCC preven-ting and therapy.